Inflammatory Rheumatic Diseases in Germany: Numbers adjusted
1.8 million people affected The number of people with inflammatory rheumatic diseases in Germany remains high at 2.6 percent, or 1.8 million people. The main…
1.8 million people affected The number of people with inflammatory rheumatic diseases in Germany remains high at 2.6 percent, or 1.8 million people. The main…
Rethinking T Cells in Lupus Nephritis New insights into lupus nephritis suggest that kidney damage may be driven less by autoantigen-specific T cells than by…
Leibniz Association recommends continued funding of the DRFZ The Senate of the Leibniz Association has published its statement regarding the evaluation of the DRFZ, recommending…
Epidemiologist from the DRFZ is a member of the Commission on family planning in immune-mediated long-term conditions Dr Yvette Meißner from the Pharmacoepidemiology Research Group…
10,024 Kilometers for the Climate In 2026, the DRFZ once again actively participated in the “Stadtradeln – Cycling for the Climate” challenge: Over the course…
Researchers at the DRFZ, Charité and TU Berlin have identified a characteristic intestinal microbiota signature in patients with IgG4-related disease. Using single-cell analysis and machine…
Transferring Research Into Practice For Patients With Rheumatic Diseases Common press release (LIT & DRFZ) The Leibniz Institute for Immunotherapy (LIT) and the German Rheumatology…